Key Opinion Leaders

For any company attempting to commercialise a drug, healthy relationships with leading physicians in relevant clinical areas can be a real bonus. Key Opinion Leaders in medical practice can influence prescribing behaviour in thier colleagues, and can represent a key plank in your marketing strategy.

But whilst locating and liaising with Key Opinion Leaders is an increasingly necessary part of marketing drugs, it can be difficult to ensure that interactions both present value for money, and avoid conflicts of interest. And with moves towards regulation of physician-pharmaceutical industry interactions, this is currently a key topic for many in both medical practice and industry.

SMi’s inaugural Key Opinion Leaders Conference is one of the first in the EU to look at this fascinating area. With an unparalleled panel of speakers, this conference represents an excellent opportunity to come to terms with the ethical and practical issues surrounding KOLs.

This event is supported by Pfizer Limited.

Hear presentations on the following topics:

• Moves towards regulation of physician-pharma entanglements in the UK and EU
• Case studies of using KOLs from top pharma companies
• Physicians’ perspectives on a KOL relationship, and developing the promotional literacy of doctors
• Discovering the right KOL, determining fair market value for services, and developing metrics to monitor your strategies 
• Different perspectives on the ethical challenges of KOL interactions

For details on our speakers for this event  and sponosorship and exhibition opportunities for future KOL events please contact amalick@smi-online.co.uk

Who should attend SMi's Key Opinion Leaders Conference?

Pharmaceutical executives specialising in:

• Medical Affairs
• Scientific Affairs
• Marketing
• Product Management
• Medical/Clinical Development
• Medical Education
• Clinical Operations
• KOL Relationship Management
• Medical Science Liaisons
• R&D
• Market Research/Analytics
• Professional Education

As well as Medical Professionals, and consultants and service providers interested in understanding pharmaceutical-physician interactions.